Tutto DSpace

Sfoglia per Soggetto "thalassemia major"

Items 1-7 di 7

    • Body composition in adult patients with thalassemia major 

      Vlychou M., Alexiou E., Thriskos P., Fezoulidis I., Vassiou K. (2016)
      Objective. To assess body composition in adult male and female patients with thalassemia major by dual-energy X-ray absorptiometry (DXA) and to compare the findings with a group of healthy age-matched controls. Methods. ...

    • Detection of extramedullary hematopoietic tissue in a patient with beta-thalassemia major on Tc99m-sestamibi parathyroid scintigraphy 

      Valotassiou V., Angelidis G., Alexiou S., Psimadas D., Tsougos I., Georgoulias P. (2019)
      A 50-year-old man with beta-thalassemia major underwent Tc-99m sestamibi parathyroid scintigraphy due to elevated parathyroid hormone and calcium serum levels. Single-photon emission computed tomography imaging of neck and ...

    • Efficacy of Interferon A-2b Monotherapy in B-Thalassemics with Chronic Hepatitis C 

      Kalafateli, M.; Kourakli, A.; Gatselis, N.; Lambropoulou, P.; Thomopoulos, K.; Tsamandas, A.; Christofidou, M.; Zachou, K.; Jelastopoulou, E.; Nikolopoulou, V.; Symeonidis, A.; Dalekos, G. N.; Lambropoulou-Karatza, C.; Triantos, C. (2015)
      Background & Aims: Monotherapy with standard or pegylated interferon (PegIFN) remains the first-line treatment for HCV infection in patients with thalassemia major (beta TM), although its long-term impact is still unknown. ...

    • Fibroblast Growth Factor 23 (FGF23) and Klotho Protein in Beta-Thalassemia 

      Stefanopoulos D., Nasiri-Ansari N., Dontas I., Vryonidou A., Galanos A., Psaridi L., Fatouros I.G., Mastorakos G., Papavassiliou A.G., Kassi E., Tournis S. (2020)
      Derangements in phosphate and calcium homeostasis are common in patients with beta-thalassemia. Fibroblast growth factor 23 (FGF23) is among the main hormones regulating phosphate levels, while several studies underline ...

    • Patients with haemoglobinopathies and chronic hepatitis C: A real difficult to treat population in 2016? 

      Zachou K., Arvaniti P., Gatselis N.K., Azariadis K., Papadamou G., Rigopoulou E., Dalekos G.N. (2017)
      Background & objectives: In the past, patients with haemoglobinopathies were at high risk of acquiring hepatitis C virus (HCV) due to multiple transfusions before HCV screening. In these patients, the coexistence of ...

    • Pulmonary function abnormalities in young adults with thalassemia major 

      Gourgoullanis, K. I.; Gouslou, A.; Papaioannou, G.; Halkias, C.; Stathakis, N.; Molyvdas, P. A. (1997)
      Thalassemia seems to be the most common genetic disorder. The pathophysiologic mechanisms for lung impairment is not clear. Lung function tests in children showed small airway obstruction and restrictive lung changes. ...

    • Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease 

      Sinakos E., Kountouras D., Koskinas J., Zachou K., Karatapanis S., Triantos C., Vassiliadis T., Goulis I., Kourakli A., Vlachaki E., Toli B., Tampaki M., Arvaniti P., Tsiaoussis G., Bellou A., Kattamis A., Maragkos K., Petropoulou F., Dalekos G.N., Akriviadis E., Papatheodoridis G.V. (2017)
      Interferon-based regimens for chronic hepatitis C (CHC) were often deferred in patients with β-thalasaemia major (β-TM) due to poor efficacy and tolerance. Current guidelines recommend direct-acting antivirals (DAAs) for ...